1. Medtech Insight
  2. >>Device Area
  3. >>Diabetic Care

From Pipe Dream To Reality: Artificial Pancreas Set To Debut

 
• By Robert Neil

Medtronic is leading the race to get an artificial pancreas to market, and by this time next year the company could be the first manufacturer to reach the finish line. The achievement would be historic, but with a group of established and young companies running about two to three years behind, Medtronic will have to continue to improve on its offerings to maintain its impressive dominance.

Diabetes

If its product stays on track, Medtronic PLC is positioned to make history in 2017 with the first artificial pancreas (AP) device to obtain US FDA approval. But while the company will likely have a monopoly of the market for at least a year or more, numerous competitors are set to follow. These new devices will drastically change and improve the way type 1 diabetes (T1D) is treated and launch a new level of competition in a market Medtronic has dominated for years.

It is no surprise that Medtronic is set to be the first company to launch an AP, a closed-loop system that links an insulin pump to a continuous glucose monitor (CGM) that can automatically determine when and how much insulin a user might need

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Diabetic Care

Abbott’s FreeStyle Libre CGM Reduces Cardiovascular Disease-Related Hospitalization

 
• By Natasha Barrow

The REFLECT studies showed a 78% reduction in cardiovascular disease-related hospitalization for people living with type 1 diabetes with prior low blood sugar episodes.

Roche To Localize CGM Manufacturing in US with $550M Indiana Site Investment

 
• By Shubham Singh

Roche’s Indianapolis site currently produces 5.2 billion Accu-Chek test strips annually and supports distribution to 53 countries. The new CGM line will add to an already diversified operational footprint, which includes R&D, laboratories, manufacturing, and IT services.

Consumer Healthtech Investment Totaled $4.5BN In 2024, But Bar Is High Amid Economic Uncertainty

 
• By Marion Webb

Global investment in consumer healthtech increased by 9% year-over-year in 2024, totaling $4.5bn, with significant interest in mental health solutions, according to Galen Growth. While the first quarter of 2025 saw raised confidence and investments, the Trump administration’s new tariffs and sweeping changes to healthcare have introduced new uncertainties.

Dexcom Puts Stelo On Amazon, Setting Up Consumer Showdown With Abbott

 
• By Shubham Singh

In addition to broader distribution, Dexcom is investing heavily in software enhancements for Stelo. The 180-day data lookback feature is just one of several planned upgrades intended to improve personalization and user engagement.

More from Device Area

Disparities — Including Financials Shortcomings — Remain In Women’s Health, Execs Say

 
• By Brian Bossetta

FemTech leaders discussed some of the barriers that remain in unlocking the full potential of the women’s health market during SiS New York last week. They also offered solutions.

Mirvie Launches Predictive Blood Test For Preeclampsia

 
• By Marion Webb

Mirvie launched Encompass, a blood test to help identify women over age 35 who are at moderate risk for preeclampsia, and will conduct additional studies to support reimbursements from payers.

Digital Health And AI Tools Advance Cardiac Event Prediction, SCAI 2025 Data Show

 
• By Shubham Singh

Out-of-hospital cardiac arrest remains one of the most challenging and resource-intensive emergencies in cardiovascular care. At SCAI 2025, clinicians presented a novel algorithm that improved triage decisions and reduced unnecessary interventions.